A reuterin-producing salt-tolerant Lactobacillus reuteri strain and its application

By salt-resistant Lactobacillus reuteri LBK produces reuterin in cheese, the problem of insufficient growth ability of lactic acid bacteria under high osmotic pressure environment is solved, effective inhibition of food-borne pathogenic bacteria is achieved, and the shelf life and food safety of cheese is improved. and do not use antibiotics.

CN117511762BActive Publication Date: 2024-11-05SHIHEZI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311186821.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-14
Publication Date
2024-11-05
Estimated Expiration
2043-09-14

AI Technical Summary

Technical Problem

The prior art has shortcomings in controlling the growth of foodborne pathogenic bacteria in cheese, especially in the environment of high osmotic pressure, and excessive use of antibiotics can lead to intestinal microbial disorders and disease-causing. Bacterial resistance.

Method used

A salt-resistant Lactobacillus reuteri LBK was developed, capable of growing in a highly osmotic environment and producing the antibacterial reuterin, for in situ production in cheese, combined with glycerol to inhibit the growth of E. coli and Staphylococcus aureus.

Benefits of technology

Lactobacillus reuteri LBK has good salt, acid and bile salt tolerance, and can grow under high osmotic pressure environments, produce effective antibacterial reuterin, extends the shelf life of cheese and improves food safety, and does not rely on it. Antibiotics, cheese has a unique flavor and a delicate taste.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117511762B_ABST
    Figure CN117511762B_ABST
Patent Text Reader

Abstract

The present invention discloses a reuterin-producing salt-tolerant Lactobacillus reuteri and its application. The Lactobacillus reuteri LBK of the present invention was deposited in the China Center for Type Culture Collection on May 24, 2021, with a deposit number of CCTCC NO: M 2021605, and a deposit address of: Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province. The strain of the present invention has excellent properties such as salt resistance, acid resistance, bile salt resistance, pepsin, trypsin tolerance and hydrophobicity, and has a certain resistance to common antibiotics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of microorganisms, and in particular relates to a reuterin-producing salt-tolerant Lactobacillus reuteri and application thereof. Background Art

[0002] Cheese is rich in nutrients such as fat, protein, carbohydrates, minerals, vitamins, etc. It may be contaminated by foodborne pathogens at any stage of production. Common sources of contamination in cheese include: Escherichia coli O157:H7, Listeria monocytogenes, Staphylococcus aureus, and Salmonella. Foodborne pathogens are the primary cause of foodborne diseases and an important source of food safety problems. In order to control these microorganisms, antibiotics are usually added, such as benzoic acid, sorbic acid and its salts, which are usually used as preservatives in dairy products to inhibit or kill foodborne pathogens in dairy products. Antibiotics restore homeostasis by inducing a stress response, leading to the death of microorganisms and a reduction in available energy for growth and other essential metabolic functions. However, excessive use of antibiotics can cause disorders in the structure of intestinal flora and even cause pathogenic bacteria to develop drug resistance. Therefore, it is particularly important to develop antibiotic substitutes that reduce the vitality of pathogenic microorganisms or control their growth.

[0003] As consumers demand for natural and “chemical-free” foods increases, biopreservation technology has gained popularity as a technology that can be used to inhibit the growth of pathogenic bacteria in foods. This approach uses naturally occurring compounds to extend the shelf life of foods and improve food safety. Biopreservation technology uses bacterial cells or metabolites of microorganisms, especially lactic acid bacteria, to inhibit the growth of undesirable microorganisms. Among bacterial strains, Lactobacillus reuteri can be used as a biopreservative because it is able to produce reuterin (3-hydroxypropanal), an aldehyde with broad inhibitory activity. Reuterin is thermostable, active over a wide pH range, resistant to proteolytic and lipolytic enzymes, and has antimicrobial activity against a variety of pathogens and food spoilage microorganisms, including Gram-positive bacteria, Gram-negative bacteria, yeasts, fungi, and protozoa, making it a potential food preservative or therapeutic adjuvant.

[0004] In addition, for the production of fermented foods, salt is usually added as a natural preservative in order to inhibit the growth of spoilage microorganisms. Therefore, the addition of salt creates a high-concentration environment that requires microorganisms to cope with. In this hyperosmotic environment, water loss in the cell is transferred outward, the cytoplasm is separated, and the physiological structure of the cell is destroyed, resulting in cessation of growth, and in severe cases, death. Therefore, the ability of lactic acid bacteria to grow and metabolize normally in an environment with high salt concentration is very important for the production of fermented foods.

[0005] Therefore, it is of great significance to develop a new biological preservative that can be applied to fermented foods with high osmotic pressure. The present invention discloses a Lactobacillus reuteri LBK strain that has salt tolerance and can be used as a biological preservative, and the application of Lactobacillus reuteri LBK combined with glycerol to produce reuterin in situ in cheese. Summary of the invention

[0006] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.

[0007] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.

[0008] Therefore, the object of the present invention is to overcome the deficiencies in the prior art and provide Lactobacillus reuteri LBK.

[0009] To solve the above-mentioned technical problems, the present invention provides the following technical solution: Lactobacillus reuteri LBK was deposited in the China Center for Type Culture Collection on May 24, 2021, with the deposit number CCTCC NO: M 2021605.

[0010] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a bacterial culture containing the Lactobacillus reuteri LBK.

[0011] As a preferred embodiment of the bacterial culture of the present invention, the bacterial culture includes bacterial liquid and bacterial agent.

[0012] Another object of the present invention is to overcome the deficiencies in the prior art and provide the use of the bacterial culture in the preparation of high osmotic pressure foods, functional foods, medicines or health products.

[0013] Another object of the present invention is to overcome the deficiencies in the prior art and provide the use of the Lactobacillus reuteri LBK in the preparation of high osmotic pressure foods, functional foods, medicines or health products.

[0014] Beneficial effects of the present invention:

[0015] (1) The strain described in the present invention has excellent properties such as salt resistance, acid resistance, bile salt resistance, pepsin, trypsin resistance and hydrophobicity, and has a certain resistance to common antibiotics.

[0016] (2) The strain of the present invention can produce the antibacterial substance reuterin. The concentration of reuterin produced after culturing in a 200 mmol / L glycerol aqueous solution for 2 h is 6.37 mmol / L. The MICs of reuterin produced by Lactobacillus reuteri LBK against Escherichia coli and Staphylococcus aureus are 0.28 mmol / L and 0.14 mmol / L, respectively.

[0017] (3) The cheese containing Lactobacillus reuteri LBK of the present invention has a unique flavor, a delicate and smooth taste, and no antibiotics are added. The fresh cheese contains 5.5×10 8 CFU / g, Streptococcus thermophilus 7.8×10 9 CFU / g, Lactobacillus bulgaricus 8.5×10 9 CFU / g, containing 39.77μmol / g of reuterin. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:

[0019] Figure 1 The colony morphology photograph (a) and bacterial morphology under Gram staining microscope (b) of Lactobacillus reuteri LBK of the present invention are shown.

[0020] Figure 2 This is the growth curve of Lactobacillus reuteri LBK of the present invention at different salt concentrations.

[0021] Figure 3 This is a comparison chart of the self-aggregation rate and hydrophobicity of Lactobacillus reuteri LBK and LGG of the present invention.

[0022] Figure 4 The reaction diagram of the reuterin solution of the present invention and L-tryptophan (a experimental group, b control group)

[0023] Figure 5 The reaction diagram of reuterin and L-tryptophan in the cheese of the present invention (a experimental group, b control group) DETAILED DESCRIPTION

[0024] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.

[0025] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0026] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.

[0027] The Lactobacillus reuteri LBK of the present invention is classified and named Lactobacillus reuteri LBK Lactobacillus reuteri LBK, and was preserved in the China Center for Type Culture Collection on May 24, 2021, with a preservation number of CCTCC NO: M 2021605, and the preservation address is: Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province.

[0028] Pepsin, trypsin and bile salts involved in the present invention were purchased from Beijing Solebow Technology Co., Ltd., and MRS culture medium and M17 culture medium were purchased from Qingdao Haibo Biotechnology Co., Ltd.;

[0029] The Lactobacillus rhamnosus GG involved in the present invention was purchased from the American Type Culture Collection (ATCC);

[0030] The Escherichia coli and Staphylococcus aureus involved in the present invention are from the characteristic microbial germplasm resource bank of the School of Food Science and Engineering of Shihezi University; the rocephalosporin (3-hydroxypropionaldehyde) involved is purchased from Shanghai McLean Biochemical Technology Co., Ltd., food-grade glycerol is purchased from Sichuan Shenlian Biotechnology Co., Ltd., and L-tryptophan is purchased from Tianjin Guangfu Fine Chemical Research Institute; the drug-sensitive paper involved is purchased from Changde Beekman Biotechnology Co., Ltd.

[0031] The culture medium involved in the embodiments of the present invention is as follows:

[0032] LRIM medium (g / L): 15.0 g raffinose, 15.0 g sodium acetate, 10.0 g peptone, 6.0 g potassium dihydrogen phosphate, 5.0 g yeast extract, 2.0 g ammonium acetate, 1.32 mL glacial acetic acid, 1.0 g Tween 80, 0.57 g magnesium sulfate, 0.12 g manganese sulfate, 0.003 g ferrous sulfate, 15.0 g agar.

[0033] mRCM-blue medium (g / L): 10.0g peptone, 10.0g beef extract powder, 5.0g yeast extract powder, 10.0g lactose, 5.0g sodium chloride, 3.0g sodium acetate, 2.0g potassium dihydrogen phosphate, 0.1g uracil, 0.25g calcium chloride, 0.2% Tween 80, 0.5g L-cysteine, 0.01% aniline blue, 15.0g agar.

[0034] LB medium (g / L): 10.0 g tryptone, 5.0 g yeast extract powder, 10.0 g NaCl.

[0035] Example 1

[0036] Isolation and identification of Lactobacillus reuteri LBK:

[0037] 1. Screening

[0038] The strain was isolated from cheese samples from the Yili pastoral area of ​​Xinjiang Uygur Autonomous Region, my country. The samples were transferred to a mortar and ground thoroughly. 10 -5 ~10 -7 The dilution was spread on an MRS plate and cultured at 37°C for 48 hours. The colony morphology of the cultured strain was observed, and a single colony with similar morphology was selected for continuous streaking purification for 3 times. The obtained single colony was numbered LBK. The above single colony was inoculated into MRS liquid culture medium and cultured for 24 hours to obtain a bacterial suspension. 20% glycerol was added to the bacterial suspension and stored at -80°C for subsequent experiments.

[0039] like Figure 1 As shown in (a), Lactobacillus reuteri LBK on MRS solid medium is milky white and opaque, round, with a smooth surface, neat edges, and a protrusion in the middle. Figure 1 As shown in (b), the strain is purple in Gram stain and is a Gram-positive bacterium with a rod shape, no flagella, and no spore formation.

[0040] 2. Identification

[0041] The genomic DNA of strain LBK was extracted and amplified with universal primers 27F / 1492R (5-AGTTTGATCMTGGCTCAG-3 and 5-GGTTACCTTGTTACGACTT-3) for bacterial 16SrDNA gene amplification to obtain PCR products, which were sent to Shanghai Sangon Biotech Co., Ltd. for sequence sequencing. The 16SrDNA sequence obtained after sequencing was 1471 bp in length, and the sequence is shown in SEQ ID NO.1:

[0042] atggctcaggatgaacgccggcggtgtgcc taatacatgc aagtcgtacgcactggccca

[0043] actgattgat ggtgcttgca cctgattgac gatggatcac cagtgagtggcggacgggtg

[0044] agtaacacgt aggtaacctg ccccggagcgggggataaca tttggaaaca gatgctaata

[0045] ccgcataaca acaaaagcca catggctttt gtttgaaaga tggctttggc tatcactctg

[0046] ggatggacct gcggtgcatt agctagttggtaaggtaacggcttaccaaggcgatgatgc

[0047] atagccgagt tgagagactgatcggccaca atggaactga gacacggtcc atactcctac

[0048] gggaggcagc agtagggaat cttccacaat gggcgcaagc ctgatggagc aacaccgcgt

[0049] gagtgaagaa gggtttcggc tcgtaaagct ctgttgttggagaagaacgt gcgtgagagt

[0050] aactgttcac gcagtgacggtatccaacca gaaagtcacggctaactacgtgccagcagc

[0051] cgcggtaata cgtaggtggc aagcgttatc cggatttatt gggcgtaaagcgagcgcagg

[0052] cggttgctta ggtctgatgt gaaagccttc ggcttaaccgaagaagtgca tcggaaaccg

[0053] ggcgacttga gtgcagaaga ggacagtgga actccatgtgtagcggtgga atgcgtagat

[0054] atatggaaga acaccagtggcgaaggcggc tgtctggtct gcaactgacgctgaggctcg

[0055] aaagcatgggtagcgaacaggattagatac cctggtagtc catgccgtaa acgatgagtg

[0056] ctaggtgttggagggtttcc gcccttcagt gccggagcta acgcattaagcactccgcct

[0057] ggggagtacgaccgcaaggt tgaaactcaa aggaattgac gggggcccgc acaagcggtg

[0058] gagcatgtgg tttaattcga agctacgcga agaaccttac caggtcttga catcttgcgc

[0059] taaccttaga gataaggcgt tcccttcggggacgcaatga caggtggtgc atggtcgtcg

[0060] tcagctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaaccc ttgttactag

[0061] ttgccagcat taagttgggc actctagtga gactgccggt gacaaaccggaggaaggtgg

[0062] ggacgacgtc agatcatcat gccccttatgacctgggcta cacacgtgct acaatggacg

[0063] gtacaacgagtcgcaagctc gcgagagtaa gctaatctct taaagccgtt ctcagttcgg

[0064] actgtaggct gcaactcgcc tacacgaagt cggaatcgct agtaatcgcggatcagcatg

[0065] ccgcggtgaa tacgttcccgggccttgtac acaccgcccgtcacaccatgggagtttgta

[0066] acgcccaaagtcggtggcct aacctttatgg

[0067] The sequencing results were compared with the 16SrDNA sequences in the NCBI database for homology analysis. The BLAST comparison results showed that strain LBK was Lactobacillus reuteri. The strain was deposited in the China Center for Type Culture Collection on May 24, 2021, with the deposit number CCTCCNO: M 2021605.

[0068] Example 2

[0069] Evaluation of salt tolerance of Lactobacillus reuteri LBK:

[0070] The activated Lactobacillus reuteri LBK obtained in Example 1 was inoculated at a 2% inoculum into MRS broth containing 0%, 2%, 4%, and 6% NaCl (ω / ω) and cultured for 30 h. The absorbance was measured at 600 nm every 2 h.

[0071] The results are as follows Figure 2 As shown in the figure, the strain can grow at 0%, 2%, 4%, and 6% NaCl concentrations. As the NaCl concentration increases, the bacterial concentration gradually decreases. The results show that the strain has good salt tolerance. After culturing at 0% NaCl concentration for 24 hours, the number of viable cells of Lactobacillus reuteri LBK is 1.6×10 9 CFU / mL, the number of viable bacteria at 6% NaCl concentration reached 7.7×10 8 CFU / mL.

[0072] See Table 1 for the tolerance of different Lactobacillus reuteri after culturing at 6% NaCl concentration for 6 h.

[0073] Table 1

[0074]

[0075] Note: Different letters in the table indicate significant differences between different strains under the same conditions (P < 0.01).

[0076] It can be seen that the survival rate of Lactobacillus reuteri LBK of the present invention is 89.00%, and the survival rate of Lactobacillus reuteri ATCC53608 is 36.33%. The survival rate of Lactobacillus reuteri LBK is about 2.45 times that of Lactobacillus reuteri ATCC53608. It can be seen that the salt tolerance of Lactobacillus reuteri LBK is significantly better than that of Lactobacillus reuteri ATCC53608.

[0077] Example 3

[0078] Evaluation of the tolerance of Lactobacillus reuteri LBK to the gastrointestinal environment

[0079] After the second generation activation of the strain Lactobacillus reuteri LBK of the present invention and the commercial strain LGG, the bacterial liquid at the end of logarithmic growth was taken, centrifuged at 5000×g and 4°C for 15 min, washed twice with PBS buffer (pH 7.2), and then respectively performed the following operations:

[0080] (1) Resuspend in PBS buffer at pH 2.0, 3.0 and 4.0. After incubation at 37°C for 2 h, count the number of viable cells on MRS agar plates to determine resistance to low pH.

[0081] (2) The cells were resuspended in a PBS solution containing pepsin (3 mg / mL), pH 2.0, and incubated at 37°C for 0 and 3 h before counting to assess the pepsin tolerance of the strain.

[0082] (3) Resuspend in PBS solution (pH 8.0) containing trypsin (1 mg / mL) and incubate in trypsin solution at 37°C for 0 and 4 h before counting to assess trypsin resistance.

[0083] (4) Resuspended in PBS solution (pH 8.0) containing 0.3% (ω / v) bile salts. After incubation at 37°C for 0 and 4 h, the bile salt tolerance of the strain was evaluated by viable cell count.

[0084] The results are shown in Table 2. Lactobacillus reuteri LBK has good tolerance. Under pH 2.0 environment, the survival rate after 2h incubation was 98.95%, while the commercial control strain LGG had no detectable viable count; the survival rate of Lactobacillus reuteri LBK after 3h treatment in pepsin solution was 84.95%, while LGG had no detectable viable count. The survival rate of Lactobacillus reuteri LBK after 4h treatment in trypsin solution could reach 101.08%, which was significantly higher than LGG; the survival rate after 4h incubation in 0.3% bile salt solution was 93.04%, which was not significantly different from LGG with excellent tolerance.

[0085] Table 2 Tolerance results

[0086]

[0087] Example 4

[0088] Evaluation of antibiotic susceptibility of Lactobacillus reuteri LBK

[0089] The drug sensitivity paper method was used to determine the resistance to ten common antibiotics (vancomycin, streptomycin, ampicillin, tetracycline, gentamicin, chloramphenicol, kanamycin, metronidazole, clindamycin, erythromycin). After the strain was activated, 100 μL of the bacterial solution at the end of logarithmic growth was spread on MRS agar medium. After the plate was slightly dry, the drug sensitivity paper was attached to the surface of the medium with sterile tweezers. After culturing at 37°C for 48 hours, the diameter of the transparent circle was measured.

[0090] The results are shown in Table 3, "S" stands for sensitive, "I" stands for intermediate, and "R" stands for resistant. Lactobacillus reuteri LBK has certain differences in tolerance to antibiotics. The strain is resistant to vancomycin, streptomycin, ampicillin, tetracycline, gentamicin, and metronidazole, and is sensitive to chloramphenicol, clindamycin, and erythromycin. The results of drug resistance indicate that Lactobacillus reuteri LBK is not affected by these antibiotic treatments and may help maintain the natural balance of intestinal flora during antibiotic treatment.

[0091] Table 3 Antibiotic sensitivity

[0092] antibiotic name Drug content of paper disc (μg / disc) Diameter of inhibition zone (mm) Antibiotic resistance Vancomycin 30 0 R Streptomycin 10 10 R Ampicillin 10 0 R tetracycline 30 12.7 R Gentamycin 10 11.3 R Chloramphenicol 30 41.4 S Kanamycin 30 14.2 I Metronidazole 5 0 R Clindamycin 2 43.3 S Erythromycin 15 27.3 S

[0093] Example 5

[0094] Self-aggregation rate and hydrophobicity of Lactobacillus reuteri LBK:

[0095] After the second generation activation, 5000×g of bacterial liquid at the end of logarithmic growth and centrifugation for 15 min at 4° C. are taken from the strain Lactobacillus reuteri LBK and the commercial strain LGG, bacterial bodies are collected, washed twice with PBS buffer (pH 7.2), and then the absorbance of the bacterial suspension at 600 nm is adjusted to about 0.5 (A0) with PBS buffer, and statically cultured at 37° C. After 2 hours, 200 μL of the upper suspension is gently drawn without shaking to measure the absorbance (At), and the self-aggregation rate is calculated according to formula (1).

[0096] Take 3 mL of the bacterial suspension with an adjusted absorbance of about 0.5 (H0) and add it to a round-bottom test tube with a diameter of 10 mm, then add 1 mL of xylene, shake on a vortex mixer for 2 minutes, let it stand for 15 minutes, and after stratification, use a sterile syringe to absorb the lower aqueous phase, measure the absorbance (Ht) at 600 nm, and calculate the hydrophobicity according to formula (2):

[0097] A=(1-At / A0)×100% (1)

[0098] H=(1-Ht / H0)×100% (2)

[0099] The results are as follows Figure 3 As shown in the figure, the self-aggregation rate of Lactobacillus reuteri LBK after 2 hours of culture was 15.74%. The strain had a certain self-aggregation ability, but it was lower than 33.20% of LGG. After being treated with xylene, the hydrophobicity of LGG and LBK was 31.50% and 66.90%, respectively, and the hydrophobicity of LBK was significantly higher than that of LGG. The results of self-aggregation rate and hydrophobicity showed that the strain had the ability to adhere to the human intestine, laying the foundation for its probiotic effect.

[0100] Example 6

[0101] Lactobacillus reuteri LBK produces reuterin and its antibacterial properties:

[0102] 1. Production and determination of reuterin

[0103] Lactobacillus reuteri LBK preserved in 20% glycerol at -80°C was inoculated into MRS liquid culture medium at a 2% inoculation rate and cultured at 37°C for 18 hours.

[0104] The cultured bacterial solution was inoculated into MRS solution containing 20 mmol / L glycerol at a 2% inoculum and cultured at 37° C. for 18 h. The cultured bacterial solution was centrifuged (5000×g, 4° C., 15 min) and washed twice with PBS buffer (pH 7.2).

[0105] The obtained bacterial cells were resuspended in a 200 mmol / L glycerol aqueous solution and cultured at 37°C for 2 hours. The bacterial suspension was centrifuged at 10,000 × g and 4°C for 10 minutes to separate reuterin. The supernatant was recovered and filtered, and the filtrate was considered to be the reuterin water extract.

[0106] 2. Reuterin quantification

[0107] Mix 1 mL of the filtrate with 0.75 mL of 0.01 mol / L L-tryptophan solution (dissolved in 0.05 mol / L hydrochloric acid) and 3 mL of hydrochloric acid (12 mol / L), and place in a 37°C water bath for 20 min. Reuterin dehydrates in the presence of hydrochloric acid to generate acrolein, which reacts with tryptophan to produce a purple color reaction, and the absorbance is read at 560 nm. Draw a standard curve for reuterin content in the concentration range of 0-0.7 mmol / L.

[0108] Reuterin color reaction Figure 4 As shown, the reuterin content of Lactobacillus reuteri LBK obtained by culturing it in 200 mmol / L glycerol aqueous solution for 2 hours was 6.37 mmol / L.

[0109] 3. Determination of the minimum inhibitory concentration (MIC) of reuterin

[0110] The MIC of reuterin was determined using the serial microdilution method. Escherichia coli and Staphylococcus aureus were inoculated into LB medium and cultured at 37°C for 18 hours, and the bacterial concentration was adjusted to 5LogCFU / mL as indicator bacteria. 100μL of indicator bacterial solution and 100μL of two-fold serial dilution solution of reuterin were added to a 96-well plate, and the OD value was measured at 600nm after culture at 37°C for 18 hours.

[0111] The MICs of reuterin against Escherichia coli and Staphylococcus aureus are 0.28mmol / L and 0.14mmol / L, respectively.

[0112] The results showed that reuterin could inhibit the growth of indicator bacteria at a relatively low concentration. 6.37mmol / L of Lactobacillus reuteri LBK in a 200mmol / L glycerol aqueous solution could achieve an antibacterial effect.

[0113] Example 7

[0114] Production of Lactobacillus reuteri LBK cheese and in situ production of reuterin

[0115] 1. Cheese production process:

[0116] Raw milk → Add starter → Add glycerin, rennet, sugar, salt → Filter and drain whey → Press into shape → Cut and package → Refrigerate and ripen

[0117] Commercial starter culture (Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus) from Danisco was added at 2% (corresponding to a cell count of 1.4 × 10 8 CFU / mL) was added to pasteurized milk containing 6% fat and 2% carbohydrate. The activated Lactobacillus reuteri LBK culture was centrifuged (5000×g, 15 min, 4°C), washed twice, and then added to 5% (corresponding to a cell number of 1.4×10 8 CFU / mL) inoculum was added into milk.

[0118] After 20 minutes, 200mmol / L of food-grade glycerol and 0.1% rennet were added. After 40 minutes, 6% white sugar and 0.5% NaCl were added. After curdling, the whey was filtered out and the curd was distributed into cylindrical molds, which were pressed at 1.5-2 atmospheres and matured at 4°C.

[0119] The control group consisted of cheese made using a commercial starter culture.

[0120] 2. Determination of viable bacteria count and reuterin in cheese

[0121] LRIM medium was used for Lactobacillus reuteri counts, M17 medium was used for Streptococcus thermophilus counts, and mRCM-blue medium was used for Lactobacillus bulgaricus counts. The determination method of reuterin in cheese is:

[0122] Take 2g of cheese, add 4mL of distilled water, and continue stirring for 10min. The stirred solution is centrifuged at 10000×g, 4°C for 10min, and the supernatant is filtered using a 0.22μm filter membrane. The reaction method is the same as Example 5. Add reuterin standard to the control group cheese to prepare the cheese reuterin standard curve.

[0123] The cheese fermented by Lactobacillus reuteri has a smooth texture, good sensory quality and rich aroma. 8 CFU / g, Streptococcus thermophilus 7.8×10 9 CFU / g, Lactobacillus bulgaricus 8.5×10 9 CFU / g.

[0124] Reuterin color reaction Figure 5 As shown, the content is 39.77μmol / g. Studies have shown that 2.19μmol / g of reuterin in cheese can inhibit the reproduction of spoilage bacteria and pathogenic bacteria in cheese.

[0125] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. Lactobacillus reuteri ( Lactobacillus reuteri )LBK, deposited in the China Center for Type Culture Collection on May 24, 2021, with the deposit number CCTCC NO: M 2021605.

2. A bacterial culture containing the Lactobacillus reuteri LBK as claimed in claim 1.

3. The Lactobacillus reuteri of claim 1 ( Lactobacillus reuteri ) Application of LBK in cheese preparation.